Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the diagnostic 64Cu SAR-Bombesin trial (BOP) for patients with prostate cancer is open for recruitment in Australia.
BOP
(Copper-64 SAR Bombesin in PSMA negative Prostate Cancer (BOP) is a Phase II
investigator-initiated trial (IIT) in up to 30 patients led by Prof Louise Emmett
at St Vincent’s Hospital Sydney. The BOP trial will be assessing the safety of
64Cu-SAR-Bombesin as well as looking at the diagnostic potential for men with
negative prostate specific membrane antigen (PSMA) positron emission tomography
(PET) or low PSMA expression disease in patients with suspected biochemical
recurrence (BCR) of their prostate cancer and patients with metastatic castrate
resistant prostate cancer (mCRPC) who are not eligible for PSMA therapy. The
trial will be imaging with 64Cu SAR-Bombesin on the day of administration as
well as at later timepoints.
To
read more please visit:
Imaging
trial with SAR-Bombesin in prostate cancer opens for recruitment in Australia
Source:
clarity